| Literature DB >> 30744171 |
Kai-Yin Hung1,2, Yu-Mu Chen3,4, Chin-Chou Wang5,6, Yi-Hsi Wang7, Chiung-Yu Lin8, Ya-Ting Chang9, Kuo-Tung Huang10, Meng-Chih Lin11,12, Wen-Feng Fang13,14.
Abstract
Immune dysfunction is seen both in sepsis patients and in those with malnutrition. This study aimed to determine whether insufficient nutrition and immune dysfunction have a synergistic effect on mortality in critically ill septic patients. We conducted a prospective observational study from adult sepsis patients admitted to intensive care units (ICUs) between August 2013 and June 2016. Baseline characteristics including age, gender, body mass index, NUTRIC, Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure Assessment (SOFA) scores were recorded. Immune dysfunction, defined by human leukocyte antigen DR (HLA-DR) expression, was tested at days 1, 3, and 7 of ICU admission. The study included 151 patients with sepsis who were admitted to the ICU. The 28-day survivors had higher day 7 caloric intakes (89% vs 73%, p = 0.042) and higher day 1-HLA-DR expression (88.4 vs. 79.1, p = 0.045). The cut-off points of day 7 caloric intake and day 1-HLA-DR determined by operating characteristic curves were 65.1% and 87.2%, respectively. Immune dysfunction was defined as patients with day 1-HLA-DR < 87.2%. Insufficient nutrition had no influence on survival outcomes in patients with immune dysfunction. However, patients with insufficient nutrition had poor prognosis when they were immune competent. Insufficient nutrition and immune dysfunction did not have a synergistic effect on mortality in critically ill septic patients.Entities:
Keywords: HLA-DR; ICU; nutrition; sepsis
Mesh:
Year: 2019 PMID: 30744171 PMCID: PMC6412372 DOI: 10.3390/nu11020367
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Patient recruitment and assignment.
Clinical characteristics and immune status between 28-day survivors and non-survivors. (n = 151) *.
| All ( | Non-Survivor ( | Survivor ( |
| |
|---|---|---|---|---|
| Age (years), mean (SD) | 67.3 (15.1) | 67.1 (13.5) | 67.4 (15.5) | 0.758 |
| Male, n (%) | 60 (39.7) | 13 (43.3) | 47 (38.8) | 0.653 |
| Body Mass Index, mean (SD) | 23.2 (5.0) | 24.6 (4.6) | 22.8 (5.0) | 0.056 |
| Coronary artery disease, n (%) | 45 (29.8) | 8 (26.7) | 37 (30.6) | 0.675 |
| Hypertension, n (%) | 87 (57.6) | 18 (60.0) | 69 (57.0) | 0.768 |
| Diabetes mellitus, n (%) | 75 (49.7) | 16 (53.3) | 59 (48.8) | 0.654 |
| Stroke, n (%) | 32 (21.2) | 6 (20.0) | 26 (21.5) | 0.858 |
| Chronic kidney disease, n (%) | 34 (22.5) | 9 (30.0) | 25 (20.7) | 0.273 |
| Infection focus | 0.068 | |||
| Lung | 95 (62.9) | 16 (16.8) | 79 (83.2) | |
| Urinary tract | 20 (13.2) | 2 (10.0) | 18 (90.0) | |
| Intra-abdomen | 6 (4.0) | 1 (16.7) | 5 (83.3) | |
| Others | 30 (19.9) | 11 (36.7) | 19 (63.3) | |
| Hemodialysis, n (%) | 30 (19.9) | 8 (26.7) | 22 (73.3) | 0.297 |
| Cancer, n (%) | 29 (19.2) | 7 (23.3) | 22 (18.2) | 0.209 |
| Cirrhosis, n (%) | 6 (4) | 3 (10) | 3 (2.5) | 0.059 |
| SOFA score, mean (SD) | 9.5 (3.6) | 11.9 (4.2) | 8.9 (3.2) | <0.001 |
| APAHCE-II, mean (SD) | 26.01 (8.77) | 27.57 (7.77) | 25.62 (8.99) | 0.240 |
| Interleukin-6, pg/mL, mean (SD) | 313.2 (1351.4) | 134.1 (293.7) | 1035.8 (2901.0) | 0.100 |
| NUTRIC score, mean (SD) | 5.7 (1.9) | 6.3 (2.0) | 5.5 (1.8) | 0.023 |
| Day 1 caloric intake, mean (SD) | 617.7 (439.8) | 490.2 (444.6) | 649.1 (434.8) | 0.081 |
| Day 1 caloric meet, mean (SD) | 0.43 (0.30) | 0.34 (0.31) | 0.45 (0.30) | 0.069 |
| Day 1 protein intake, g, mean (SD) | 18.6 (17.7) | 13.5 (15.8) | 19.8 (18.0) | 0.089 |
| Day 1 HLA-DR (%), mean (SD) | 86.5 (15.8) | 79.1 (21.5) | 88.4 (13.5) | 0.045 |
| Day 3 caloric intake, mean (SD) ** | 1053.4 (496.1) | 882.0 (573.0) | 1087.1 (475.0) | 0.070 |
| Day 3 caloric meet, mean (SD) | 0.74 (0.36) | 0.62 (0.42) | 0.76 (0.34) | 0.072 |
| Day 3 protein intake, g, mean (SD) | 36.9 (22.4) | 37.9 (21.9) | 36.5 (22.7) | 0.737 |
| Day 3 HLA-DR (%), mean (SD) | 89.8 (12.2) | 85.1 (15.4) | 90.6 (11.4) | 0.052 |
| Day 7 caloric intake, mean (SD) *** | 869.8 (304.7) | 730.4 (310.3) | 890.8 (299.7) | 0.049 |
| Day 7 caloric meet, mean (SD) | 0.87 (0.30) | 0.73 (0.31) | 0.89 (0.30) | 0.042 |
| Day 7 protein intake, g, mean (SD) | 48.3 (20.7) | 43.8 (21.3) | 50.3 (20.3) | 0.114 |
| Day 7 HLA-DR (%), mean (SD) | 93.6 (9.9) | 83.9 (21.1) | 94.7 (7.1) | 0.085 |
* Data were measured at the first day of ICU admission unless otherwise mentioned; ** 140 patients who survived at day 3 were analyzed for day 3 caloric meet and day 3 HLA-DR; *** 122 patients who survived at day 7 were analyzed for day 7 caloric meet and day 7 HLA-DR; Abbreviations: SOFA: Sequential Organ Failure Assessment; HLA-DR: Human Leukocyte Antigen DR.
Clinical characteristics and immune status between patients within different quartiles of caloric meet (n = 122).
| Day 7 Caloric Meet | First Quartile | Second Quartile | Third Quartile | Fourth Quartile |
|
|---|---|---|---|---|---|
| Age (years), mean (SD) | 69.6 (15.6) | 68.2 (15.5) | 69.7 (12.8) | 65.7 (16.6) | 0.710 |
| Male, n (%) | 11 (36.7) | 7 (22.6) | 11 (35.5) | 19 (63.3) | 0.011 |
| Body Mass Index, mean (SD) | 22.8 (4.7) | 23.0 (6.8) | 22.0 (4.7) | 23.8 (4.1) | 0.598 |
| Coronary artery disease, n (%) | 9 (30.0) | 4 (12.9) | 9 (29.0) | 13 (43.3) | 0.074 |
| Hypertension, n (%) | 14 (46.7) | 20 (64.5) | 18 (58.1) | 17 (56.7) | 0.568 |
| Diabetes mellitus, n (%) | 13 (43.3) | 12 (38.7) | 15 (48.4) | 18 (60.0) | 0.383 |
| Stroke, n (%) | 8 (26.7) | 8 (26.7) | 5 (16.1) | 4 (13.3) | 0.241 |
| Chronic kidney disease, n (%) | 11 (36.7) | 8 (25.8) | 3 (9.7) | 4 (13.3) | 0.041 |
| Cancer, n (%) | 12 (40.0) | 5 (16.1) | 5 (16.1) | 3 (10.0) | 0.021 |
| Cirrhosis, n (%) | 3 (10.0) | 0 (0.0) | 1 (3.2) | 1 (3.3) | 0.252 |
| SOFA score, mean (SD) | 10.7 (4.6) | 8.9 (3.2) | 9.0 (3.0) | 8.7 (2.8) | 0.105 |
| Interleukin-6, µ/mL, mean (SD) | 198.2 (326.0) | 163.2 (327.2) | 94.3 (159.8) | 56.2 (107.3) | 0.118 |
| NUTRIC score, mean (SD) | 5.7 (2.0) | 5.6 (1.9) | 5.7 (1.8) | 5.3 (1.8) | 0.783 |
| HLA-DR (%), mean (SD) | 81.9 (17.8) | 87.4 (13.8) | 90.4 (13.0) | 89.1 (13.4) | 0.122 |
Abbreviations: SOFA: Sequential Organ Failure Assessment; HLA-DR: Human Leukocyte Antigen DR.
Figure 2(A) The ROC curve of day 1-HLA-DR for 28-day mortality prediction. The best cut-off point for day 1-HLA-DR determined using the ROC curve and Youden index was 87.2%. (B) The ROC curve of day 7 caloric meet for 28-day mortality prediction. The best cut-off point for day 7 caloric meets determined using the ROC curve and Youden index was 65.1%. PV: predictive value.
Figure 3Impact of day 7 caloric meet on survival outcome in patients with or without immune dysfunction. Patients with higher day 7 caloric meet and normal immune status had the best prognosis. Patients with lower day 7 caloric meet and normal immune status had a worse prognosis.
Figure 4Impact of day 7 caloric meet on survival outcome in patients with high or low NUTRIC score. Patients with a lower day 7 caloric meet had a poor prognosis both in those with (A) low nutritional risk (NUTRIC score 0–5) and (B) high nutritional risk (NUTRIC score 6–10).
Multivariate analysis of clinical characteristics and immune status for 28-day mortality prediction. (n = 122).
| β | S.E. | Wals | df | sig | Exp(β) (95% C.I.) | |
|---|---|---|---|---|---|---|
| NUTRIC score | 0.004 | 0.147 | 0.001 | 1 | 0.976 | 1.004 (0.753–1.339) |
| Day 1 HLA-DR (≥87.2% vs. <87.2%) | 0.544 | 0.574 | 0.898 | 1 | 0.343 | 1.723 (0.559–5.307) |
| day 7 caloric meet (≥65.1% vs. <65.1%) | 1.280 | 0.560 | 5.220 | 1 | 0.022 | 3.596 (1.200–10.782) |
Abbreviations: S.E.: standard error; Wals: rating scale; df: degrees of freedom; sig: statistical significance; Exp(β): odds ratio; C.I.: confidence interval.